Adiponectin is the name originated from its distinctive molecular
characteristics ("adipo" + "nectin" = "adiponectin") as it is a product
of novel gene apM1 which is specific to adipocytes and uniquely possess
a collagen-like domain with a nectin-like adherent property. Adiponectin
is the most abundant peptide secreted by adipocytes, whose altered
levels play a central role in obesity-related diseases, including
insulin resistance/type 2 diabetes and cardiovascular disease. It is
known to exert anti-diabetic and anti-atherosclerotic effects via
adiponectin receptors (Adipors); AdipoR1 and AdipoR2. Adiponectin has
direct actions in liver, skeletal muscle and the vasculature.
Adiponectin administration in humans and rodents has
insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects and
in certain settings, also decreases body weight. Therefore, adiponectin
replacement therapy in humans may suggest potential versatile
therapeutic targets in the treatment of obesity, insulin resistance/type
2 diabetes, cardiovascular disease and atherosclerosis.